On July 15, 2025, in Zhengzhou, China, WixBio fulfilled a repeat order from a Turkish client, shipping 4,000 bottles of 500ml inactivated hexavalent vaccine (a six-in-one shot) for Newcastle Disease (ND-G7 strain), Avian Influenza H9 subtype (H9), and Duck Adenovirus types 4, 8, and 11 (FADV-4, FADV-8, FADV-11). The vaccines were shipped via a complete cold-chain system to Turkey, ensuring safe and timely delivery.
This order demonstrates the high value our Turkish client places on WixBio’s products, reflecting their trust in our quality, packaging, and prompt delivery. Since using the initial batches, they’ve reported an excellent immune response, high antibody levels, and broad protection, receiving great feedback from local farms and veterinary clinics.
This hexavalent vaccine is a tailored formula designed to tackle common poultry diseases in Turkey, effectively preventing Newcastle Disease, Avian Influenza, and multiple serotypes of Duck Adenovirus infections, significantly cutting down morbidity and mortality while boosting farm efficiency.
To maintain the vaccine’s full activity during transport, WixBio utilized a comprehensive cold-chain system with GPS temperature monitoring, ensuring seamless management from the factory to the client and maintaining reliable vaccine quality.
The head of WixBio’s Overseas Business Division said: “We’re truly grateful for our Turkish client’s ongoing trust and support. Every repeat order proves the strength of our products and services. We’ll keep pushing high standards to deliver top-notch animal health solutions worldwide.”
This shipment further solidifies WixBio’s presence in the Turkish market and highlights our growing expertise in international customized vaccine supply and cold-chain logistics.
About WixBio
WixBio is a high-tech company specializing in the research and development, production, and sales of veterinary drugs and animal vaccines, backed by a robust quality management system and a dedicated technical support team. Our products cover poultry, livestock, and more, with operations across Asia, the Middle East, Africa, and Europe, where we’re well-respected across global markets.
